{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:12:00Z","timestamp":1789985520709,"version":"4.0.1"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,6]]},"abstract":"<jats:p>\n                    This study aimed to develop and validate a clinical model for predicting the risk of nonalcoholic fatty liver disease (NAFLD) by using data from a cross-sectional study. This investigation utilized data from the Dryad database and employed multivariable logistic regression analysis, restricted cubic spline, and nomogram analysis to achieve comprehensive insights. The discrimination and calibration of the nomogram were evaluated using the receiver operating characteristic curve and calibration plot. A total of 1072 patients were included in the study, including 456 with non-NAFLD and 616 with NAFLD. Significant differences were observed in terms of sex, body mass index (BMI), tobacco, hypertension, diabetes, alanine aminotransferase (ALT), aspartate aminotransferase (AST), ALT\/AST ratio, uric acid (UA), fasting blood glucose (FBG), triglyceride (TG), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, systolic blood pressure, and diastolic blood pressure (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05 for all comparisons). Multivariable logistic regression analysis indicated that sex, BMI, diabetes, ALT\/AST ratio, UA, FBG, and TG were associated with an increased risk of NAFLD. Restricted cubic spline indicated a nonlinear relationship between the risk of NAFLD and variables including ALT\/AST ratio, FPG, TG, and UA (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    for nonlinearity\u2005&lt;\u2005.01). The variables in the nomogram included BMI, diabetes, ALT\/AST ratio, UA, FBG, and TG. The value of area under the curve was 0.790, indicating that the nomogram prediction model exhibited significant discriminatory accuracy. A reliable clinical model for predicting the risk of NAFLD was developed using readily available clinical data. The model can assist clinicians in identifying individuals with an increased risk of NAFLD, enabling early interventions for preventing and managing this prevalent liver disease.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000039437","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T04:05:30Z","timestamp":1730865930000},"page":"e39437","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Clinical model to predict the risk of nonalcoholic fatty liver disease: A secondary analysis of data from a cross-sectional study"],"prefix":"10.1097","volume":"103","author":[{"given":"Bo","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Guizhou Aerospace Hospital, Zunyi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1245-8702","authenticated-orcid":false,"given":"Xiang","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Guizhou Aerospace Hospital, Zunyi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250505","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease.","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"R2-20250505","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease.","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"R3-20250505","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","article-title":"New trends on obesity and NAFLD in Asia.","volume":"67","author":"Fan","year":"2017","journal-title":"J Hepatol"},{"key":"R4-20250505","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1053\/j.gastro.2019.12.053","article-title":"AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review.","volume":"158","author":"Loomba","year":"2020","journal-title":"Gastroenterology"},{"key":"R5-20250505","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons.","volume":"79","author":"Le","year":"2023","journal-title":"J Hepatol"},{"key":"R6-20250505","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbcan.2018.11.005","article-title":"Advancing the understanding of NAFLD to hepatocellular carcinoma development: from experimental models to humans.","volume":"1871","author":"Chen","year":"2019","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"R7-20250505","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.3390\/medicina59081427","article-title":"Perspective on the role of gut microbiome in the treatment of hepatocellular carcinoma with immune checkpoint inhibitors.","volume":"59","author":"Abenavoli","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"R8-20250505","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cld.2017.08.007","article-title":"Pathophysiology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis.","volume":"22","author":"Manne","year":"2018","journal-title":"Clin Liver Dis"},{"key":"R9-20250505","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"R10-20250505","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies.","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"R11-20250505","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/j.2040-4603.2012.tb00425.x","article-title":"Lack of exercise is a major cause of chronic diseases.","volume":"2","author":"Booth","year":"2012","journal-title":"Compr Physiol"},{"key":"R12-20250505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15380","article-title":"Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.","volume":"15","author":"Shyangdan","year":"2011","journal-title":"Health Technol Assess"},{"key":"R13-20250505","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s42000-022-00377-8","article-title":"Non-invasive diagnosis and staging of non-alcoholic fatty liver disease.","volume":"21","author":"Kechagias","year":"2022","journal-title":"Hormones (Athens)"},{"key":"R14-20250505","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJM200102153440706","article-title":"Liver biopsy.","volume":"344","author":"Bravo","year":"2001","journal-title":"N Engl J Med"},{"key":"R15-20250505","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1445-5994.2006.01216.x","article-title":"Twenty-year audit of percutaneous liver biopsy in a major Australian teaching hospital.","volume":"36","author":"van der Poorten","year":"2006","journal-title":"Intern Med J"},{"key":"R16-20250505","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.anndiagpath.2010.08.001","article-title":"Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology.","volume":"15","author":"Gawrieh","year":"2011","journal-title":"Ann Diagn Pathol"},{"key":"R17-20250505","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.3748\/wjg.v19.i22.3375","article-title":"What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?","volume":"19","author":"Tarantino","year":"2013","journal-title":"World J Gastroenterol"},{"key":"R18-20250505","doi-asserted-by":"crossref","first-page":"7392","DOI":"10.3748\/wjg.v20.i23.7392","article-title":"Radiologic evaluation of nonalcoholic fatty liver disease.","volume":"20","author":"Lee","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R19-20250505","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jhep.2010.01.008","article-title":"Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations.","volume":"52","author":"Lee","year":"2010","journal-title":"J Hepatol"},{"key":"R20-20250505","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/hep.22241","article-title":"A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients.","volume":"47","author":"Campos","year":"2008","journal-title":"Hepatology"},{"key":"R21-20250505","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1478-3231.2005.01209.x","article-title":"Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease.","volume":"26","author":"Palekar","year":"2006","journal-title":"Liver Int"},{"key":"R22-20250505","doi-asserted-by":"crossref","first-page":"e072489","DOI":"10.1136\/bmjopen-2023-072489","article-title":"Association of fat-to-muscle ratio with non-alcoholic fatty liver disease: a single-centre retrospective study.","volume":"13","author":"Yan","year":"2023","journal-title":"BMJ Open"},{"key":"R23-20250505","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00535-012-0650-8","article-title":"Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal cohort study.","volume":"48","author":"Miyake","year":"2013","journal-title":"J Gastroenterol"},{"key":"R24-20250505","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1210\/jc.2015-3444","article-title":"Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record prospective studies.","volume":"101","author":"Loomis","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R25-20250505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40265-012-0004-0","article-title":"Nonalcoholic fatty liver disease: current issues and novel treatment approaches.","volume":"73","author":"Lomonaco","year":"2013","journal-title":"Drugs"},{"key":"R26-20250505","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature05485","article-title":"Inflammation and metabolic disorders.","volume":"444","author":"Hotamisligil","year":"2006","journal-title":"Nature"},{"key":"R27-20250505","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.23280","article-title":"Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications.","volume":"51","author":"Fabbrini","year":"2010","journal-title":"Hepatology"},{"key":"R28-20250505","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes.","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"R29-20250505","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cld.2009.07.009","article-title":"Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis.","volume":"13","author":"Cusi","year":"2009","journal-title":"Clin Liver Dis"},{"key":"R30-20250505","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.tem.2008.08.005","article-title":"Insulin resistance, inflammation, and non-alcoholic fatty liver disease.","volume":"19","author":"Tilg","year":"2008","journal-title":"Trends Endocrinol Metab"},{"key":"R31-20250505","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"R32-20250505","doi-asserted-by":"crossref","first-page":"14812","DOI":"10.1038\/s41598-023-41596-2","article-title":"Analysis of clinical features and identification of risk factors in patients with non-alcoholic fatty liver disease based on FibroTouch.","volume":"13","author":"Liao","year":"2023","journal-title":"Sci Rep"},{"key":"R33-20250505","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1572-0241.2003.07486.x","article-title":"The prevalence and etiology of elevated aminotransferase levels in the United States.","volume":"98","author":"Clark","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R34-20250505","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.14309\/ajg.0000000000000388","article-title":"Histologic findings of advanced fibrosis and cirrhosis in patients with nonalcoholic fatty liver disease who have normal aminotransferase levels.","volume":"114","author":"Gawrieh","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"R35-20250505","doi-asserted-by":"crossref","first-page":"14325","DOI":"10.1038\/srep14325","article-title":"Dose-response relationship of serum uric acid with metabolic syndrome and non-alcoholic fatty liver disease incidence: a meta-analysis of prospective studies.","volume":"5","author":"Liu","year":"2015","journal-title":"Sci Rep"},{"key":"R36-20250505","doi-asserted-by":"crossref","first-page":"e11578","DOI":"10.1371\/journal.pone.0011578","article-title":"High serum uric acid increases the risk for nonalcoholic fatty liver disease: a prospective observational study.","volume":"5","author":"Xu","year":"2010","journal-title":"PLoS One"},{"key":"R37-20250505","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.metabol.2012.08.013","article-title":"Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: liver ultrasound data from the National Health and Nutrition Examination Survey.","volume":"62","author":"Sirota","year":"2013","journal-title":"Metabolism"},{"key":"R38-20250505","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.dld.2014.09.020","article-title":"Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome.","volume":"47","author":"Lonardo","year":"2015","journal-title":"Dig Liver Dis"},{"key":"R39-20250505","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00535-013-0758-5","article-title":"Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease.","volume":"48","author":"Kawano","year":"2013","journal-title":"J Gastroenterol"},{"key":"R40-20250505","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.3390\/ijms25115640","article-title":"Metabolic dysfunction-associated steatotic liver disease: from pathogenesis to current therapeutic options.","volume":"25","author":"Portincasa","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R41-20250505","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4254\/wjh.v9.i16.715","article-title":"Non-alcoholic fatty liver disease: an expanded review.","volume":"9","author":"Benedict","year":"2017","journal-title":"World J Hepatol"},{"key":"R42-20250505","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease.","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"R43-20250505","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature.","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"R44-20250505","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14548","article-title":"Comparison of MAFLD and NAFLD diagnostic criteria in real world.","volume":"40","author":"Lin","year":"2020","journal-title":"Liver Int"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T16:00:29Z","timestamp":1746460829000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":44,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039437","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]}}}